425: Atlantic Coastal Acquisition Corp. II Announces Proposed Business Combination with Abpro Corporation

Atlantic Coastal Acquisition Corp. II (ACAB) has filed an amendment to its Registration Statement on Form S-4 regarding its proposed business combination with Abpro Corporation, a biopharmaceutical company developing antibody therapies.

Summary

• Atlantic Coastal Acquisition Corp. II (ACAB) is pursuing a business combination with Abpro Corporation at a purchase price of approximately $500 million.
• The transaction is expected to be funded through a combination of $37.6 million in PIPE financing and an estimated $7.2 million ACAB cash in trust.
• Abpro shareholders will rollover 100% of their equity, representing an expected ~78% of the pro forma equity value.
• The net proceeds are expected to fund Abpro's operations, including R&D efforts and clinical development of two lead programs.
• The targeted transaction close is expected in Q2 2024, subject to customary closing conditions and approvals.
• Abpro's pipeline includes ABP-102 (HER2/CD3) for breast and gastric cancer, ABP-201 (VEGF/ANG2) for wet AMD and DME, ABP-110 (GPC3/CD3) for liver cancer, and ABP-150 (Claudin18.2/CD3) for gastric cancer.
• Abpro has a strategic partnership with Celltrion for ABP-102, with Celltrion fully funding development and Abpro retaining a 50% share of profits worldwide, with potential payments to Abpro up to $1.75B.
• ABP-201 is being co-developed via a territorial partnership with Abpro Bio, with Abpro retaining U.S. and European Union commercial rights.
• ABP-150 has a collaboration with Nanjing Chia-Tai Tianqing Pharmaceutical, with potential milestone payments up to $405 million USD and Abpro retaining commercialization rights outside China and Thailand.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Abpro, highlighting its pipeline, partnerships, and potential market opportunities. However, it also acknowledges the risks associated with the transaction and clinical development, resulting in a moderately positive sentiment score.

Positives

• Abpro has a robust therapeutic pipeline of next-generation candidates.
• Abpro has an experienced leadership team and world-class boards.
• Abpro has established development and commercialization partnerships with industry leaders.
• Abpro's DiversImmune discovery platform is validated by global pharma and research institutions.
• Abpro's MultiMab antibody engineering platform enhances efficacy and safety.
• Abpro's ABP-102 is fully funded by Celltrion, with potential payments to Abpro up to $1.75B.
• Abpro retains a 50% share of profits worldwide for ABP-102.
• ABP-201 has shown positive results in preclinical models.
• Abpro is collaborating with Nanjing Chia-Tai Tianqing Pharmaceutical for ABP-150, with potential milestone payments up to $405 million USD.
• Abpro retains commercialization rights outside China and Thailand for ABP-150.

Negatives

• The transaction is subject to customary closing conditions and approvals, which may not be met.
• The amount of redemption requests made by ACAB's stockholders could impact the cash available for the transaction.
• The success of Abpro's pipeline candidates is subject to regulatory approval and clinical trial outcomes.
• Abpro's future financial performance is subject to significant uncertainty.
• Market opportunity estimates and growth forecasts are subject to significant uncertainty.

Risks

• The Proposed Business Combination may not be completed in a timely manner or at all.
• Failure to satisfy the conditions to the consummation of the Proposed Business Combination, including the receipt of the requisite approvals of ACABs and Abpros stockholders.
• The effect of the announcement or pendency of the Proposed Business Combination on Abpros business relationships, performance and business generally.
• The ability to maintain the listing of ACABs securities on The Nasdaq Stock Market LLC.
• The potential inability of Abpro to manage growth effectively.
• Abpros dependence on senior management and other key employees.
• The inability to successfully bring Abpros products to market (including obtaining regulatory approval).
• The early termination of any of Abpros existing agreements to develop its products.
• Abpros failure to raise additional capital or generate the significant capital necessary to maintain and expand its operations, and risks related to Abpros ability to continue as a going concern.

Future Outlook

The document outlines Abpro's anticipated clinical development timeline for its lead programs, including ABP-102, ABP-201, ABP-150, and ABP-110, with projected timelines for Phase 1, Phase 2, Phase 3, and BLA filings.

Industry Context

The announcement reflects the ongoing trend of SPAC mergers in the biotech industry, providing a pathway for private companies like Abpro to access public markets and secure funding for clinical development.

Comparison to Industry Standards

• The document mentions Celltrion, a leading biopharmaceutical company, as a partner for ABP-102, indicating a validation of Abpro's technology and potential.
• The document references Vabysmo and Eylea, two leading treatments for wet AMD, as comparators for ABP-201, highlighting Abpro's ambition to compete in this market.
• The document cites market research data from reputable sources such as Prescient and Strategic Intelligence and Data Bridge Market Research, providing context for the market opportunities for Abpro's pipeline candidates.

Stakeholder Impact

• Shareholders of ACAB and Abpro will be impacted by the business combination.
• Employees of Abpro may be affected by changes following the business combination.
• Patients with cancer and eye diseases could benefit from Abpro's pipeline candidates.
• Partners of Abpro, such as Celltrion and Nanjing Chia-Tai Tianqing Pharmaceutical, will be impacted by the progress of their collaborations.

Next Steps

• Complete the business combination between ACAB and Abpro.
• Secure necessary regulatory approvals.
• Advance clinical development of ABP-102, ABP-201, ABP-150, and ABP-110.
• File IND applications for ABP-102 and ABP-201.
• Initiate Phase 1 clinical trials for ABP-102 and ABP-201.
• Pursue additional development and commercialization partnerships.

Key Dates